shutterstock 1097370944 450x300 kCmzdz

Hampered access to innovative cancer drugs in Spain

​ ​ 

Medical societies, patient associations, and independent experts are pressing for expedited access to innovative cancer treatments in Spain, citing a noticeable lag and lack of alternatives in the process.

Spain faces a “structural problem” when assessing and funding innovative cancer drugs. Between 2017 and 2021, Spanish patients waited an average of 611 days to access innovative therapies – far above the figures for Germany and Denmark, which are 102 days and 145 days respectively.

Experts call for faster access to innovative cancer treatments in Spain

News Health
26-09-2023

Est. 4min

Access to innovative cancer treatments in Spain must be expedited, medical societies, patient associations, and independent experts urged at a conference, citing concerns over marked delays and a lack of alternatives.

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *